Find a Trial | Boxer Lab

Current Clinical Trials

The Boxer Lab is currently running numerous clinical trials at the UCSF Memory and Aging Center, approximately half treating Alzheimer’s disease (AD) and the other half treating frontotemporal dementias (FTD), including progressive supranuclear palsy (PSP). There is quite a lot of overlap between both the symptoms and the underlying biology of AD and FTD, and several of the investigational drugs are being tested in both diseases.

The main biological targets for these drugs are the proteins amyloid beta and tau. Both of these proteins become misfolded and dysfunctional during disease, clumping together in “plaques” or “tangles” and ultimately causing brain cells to die. Amyloid beta plaques are characteristic of AD, while tau tangles afflict AD and FTD. Click on the links to learn more about these proteins and other therapeutic targets, or go to the clinicaltrials.gov page for each trial below.

New trials are always launching, so if you don’t see one that fits what you’re looking for, check back in a month or two. You may also contact us at [email protected]

Open

A Phase 3 Study of Safety and Efficacy of AMX0035 in Progressive Supranuclear Palsy (ORION)

Please visit ClinicalTrials.gov for more information.

A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants With Alzheimer's Disease

Please visit ClinicalTrials.gov for more information.

AHEAD 3-4/5 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid

Please go to https://www.aheadstudy.org/ or ClinicalTrials.gov for more information.

Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of Oral Verdiperstat (BHV-3241) in Patients With Semantic Variant Primary Progressive Aphasia (svPPA) Due to TDP

Please go to ClinicalTrials.gov for more information.

Active, but no longer recruiting

A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer’s Disease - BAN2401-G000-3011 (Eisai)

Please go to ClinicalTrials.gov for more information.

Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease (I5T-MC-AACI)

Please go to ClinicalTrials.gov for more information.

Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (Aducanumab) in Subjects With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 (Biogen221AD304)

Please go to ClinicalTrials.gov for more information.

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of BIIB080 in Subjects with Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease Dementia

Please visit ClinicalTrials.gov for more information.

Closed

A First in Human Phase 1 Study in Healthy Volunteers and Heterozygous Carriers of a Loss-of-function Granulin Mutation Causative of Frontotemporal Dementia to Assess AL001 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics (AL001-1)

Please go to ClinicalTrials.gov for more information.

A Multicenter, Open-Label, Long-Term Extension Of Phase III Studies (BN29552/BN29553) Of Crenezumab In Patients With Alzheimer's Disease (BN40031)

Please go to ClinicalTrials.gov for more information.

A Multicenter, Open-Label, Long-Term Treatment Study of Intravenously Administered BIIB092 in Patients with Progressive Supranuclear Palsy Who Participated in Study CN002003 (251PP201)

Please go to ClinicalTrials.gov for more information.

A Phase 1b, 12-Month, Randomized, Double Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Salsalate in Patients with Mild to Moderate Alzheimer’s Disease (UC-SAL-AD-001)

Please go to ClinicalTrials.gov for more information.

A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel Cohort Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of Intravenously Infused BIIB092 in Patients With Four Different Primary Tauopathy Syndromes

Please go to ClinicalTrials.gov for more information.

A Phase 2 Clinical Trial of Intranasal Oxytocin for Frontotemporal Dementia (FOXY)

Please go to ClinicalTrials.gov for more information.

A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects with Early Alzheimer’s Disease (M15-566)

Please go to ClinicalTrials.gov for more information.

A Phase 2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AL001 in Heterozygous Carriers of Granulin or C9ORF72 Mutations Causative of Frontotemporal Dementia (Alector AL001-2)

Please go to ClinicalTrials.gov for more information.

A Phase 2a Open-Label Preliminary Safety, Tolerability, and Biomarker Study of Oral Fasudil in Patients with the 4-Repeat Tauopathies of Progressive Supranuclear Palsy-Richardson Syndrome or Corticobasal Syndrome (ROCKIT-1 ROCK Inhibitor in Tauopathies-1)

Please go to ClinicalTrials.gov for more information.

A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD

Please go to ClinicalTrials.gov for more information.

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer’s Disease (221AD301)

Please go to ClinicalTrials.gov for more information.

A Phase Ib, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Arm, Multiple-Dose Study to Assess The Safety, Tolerability, And Pharmacokinetics of Intravenous Crenezumab Administered in Patients With Mild to Moderate Alzheimer's Disease

Please go to ClinicalTrials.gov for more information.

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Crenezumab in Patients with Prodromal to Mild Alzheimer’s Disease (BN29552)

Please go to ClinicalTrials.gov for more information.

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy And Safety Study Of Crenezumab In Patients With Prodromal To Mild Alzheimer’s Disease (BN29553)

Please go to ClinicalTrials.gov for more information.

A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy (M15-562)

Please go to ClinicalTrials.gov for more information.

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants with Progressive Supranuclear Palsy (251PP301)

Please go to ClinicalTrials.gov for more information.

A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TPI-287 in Alzheimer’s Disease

Please go to ClinicalTrials.gov for more information.

An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (M15-563)

Please go to ClinicalTrials.gov for more information.

Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4 Study)

Please go to https://a4study.org/ and ClinicalTrials.gov for more information.

Assessment of Safety, Tolerability and Efficacy of LY3303560 in Early Symptomatic Alzheimer’s Disease (18G-MC-LMDC)

Please go to ClinicalTrials.gov for more information.